Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy

Gerrit Jan Willem Euverink; Laura Hesse; Martijn Christiaan Nawijn; Adrianus Cornelis  van der Graaf

Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy

Gerrit Jan Willem Euverink (Uitvinder), Laura Hesse (Uitvinder), Martijn Christiaan Nawijn (Uitvinder), Adrianus Cornelis van der Graaf (Uitvinder)

Onderzoeksoutput

Samenvatting

The present invention relates to a composition comprising purified natural Der p1 and purified natural Der p2 allergens for use in the treatment of house-dust mite allergy in mammals, like humans. The invention further pertains pharmaceutical compositions for allergy-specific immune therapy. Specifically, the invention discloses reduced responsiveness to subsequent house dust mite allergen exposure after treatment with a pharmaceutical composition comprising purified natural Der p1 and purified natural Der p2 characterized by reduction in Th2 cell activity and reduction in CCL20 release.

Originele taal-2	English
Octrooinummer	WO2016193126
Prioriteitsdatum	29/05/2015
Status	Published - 8-dec.-2016

Toegang tot document

https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=WO&NR=2016193126A1&KC=A1&FT=D&ND=3&date=20161208&DB=&locale=en_EP

Handle.net

Permanente koppeling

Citeer dit

@misc{e2ab3f3301e84e179e69f3bffe04715c,

title = "Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy",

abstract = "The present invention relates to a composition comprising purified natural Der p1 and purified natural Der p2 allergens for use in the treatment of house-dust mite allergy in mammals, like humans. The invention further pertains pharmaceutical compositions for allergy-specific immune therapy. Specifically, the invention discloses reduced responsiveness to subsequent house dust mite allergen exposure after treatment with a pharmaceutical composition comprising purified natural Der p1 and purified natural Der p2 characterized by reduction in Th2 cell activity and reduction in CCL20 release.",

author = "Euverink, {Gerrit Jan Willem} and Laura Hesse and Nawijn, {Martijn Christiaan} and {van der Graaf}, {Adrianus Cornelis}",

year = "2016",

month = dec,

day = "8",

language = "English",

type = "Patent",

note = "WO2016193126",

}

TY - PAT

T1 - Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy

AU - Euverink, Gerrit Jan Willem

AU - Hesse, Laura

AU - Nawijn, Martijn Christiaan

AU - van der Graaf, Adrianus Cornelis

PY - 2016/12/8

Y1 - 2016/12/8

N2 - The present invention relates to a composition comprising purified natural Der p1 and purified natural Der p2 allergens for use in the treatment of house-dust mite allergy in mammals, like humans. The invention further pertains pharmaceutical compositions for allergy-specific immune therapy. Specifically, the invention discloses reduced responsiveness to subsequent house dust mite allergen exposure after treatment with a pharmaceutical composition comprising purified natural Der p1 and purified natural Der p2 characterized by reduction in Th2 cell activity and reduction in CCL20 release.

AB - The present invention relates to a composition comprising purified natural Der p1 and purified natural Der p2 allergens for use in the treatment of house-dust mite allergy in mammals, like humans. The invention further pertains pharmaceutical compositions for allergy-specific immune therapy. Specifically, the invention discloses reduced responsiveness to subsequent house dust mite allergen exposure after treatment with a pharmaceutical composition comprising purified natural Der p1 and purified natural Der p2 characterized by reduction in Th2 cell activity and reduction in CCL20 release.

M3 - Patent

M1 - WO2016193126

ER -

Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit